Remifentanil B. Braun Caution For Usage

Special Precautions for disposal and other handling: Reconstitution: Remifentanil should be prepared for intravenous use by adding the appropriate volume (see Table 13) of one of the listed diluents as follows to give a reconstituted solution with a concentration of approximately 1 mg/ml.

Click on icon to see table/diagram/image

Shake until completely dissolved. The reconstituted solution should be clear, colourless and free of visible particles.
Further Dilution: After reconstitution, Remifentanil 1 mg/2 mg may be further diluted (see Shelf-Life under Storage for the storage conditions of the reconstituted/diluted product for the recommended diluents).
For manually-controlled infusion this medicinal product can be diluted to concentrations of 20 to 250 μg/ml (50 μg/ml is the recommended dilution for adults and 20 to 25 μg/ml for paediatric patients aged 1 year and over).
For target-controlled infusion (TCI) the recommended dilution of Remifentanil is 20 to 50 μg/ml.
The dilution is dependent upon the technical capability of the infusion device and the anticipated requirements of the patient.
One of the following solutions should be used for dilution: Water for Injections, Glucose 50 mg/ml (5%) solution for injection, Glucose 50 mg/ml (5%) solution for injection and sodium chloride 9 mg/ml (0.9 %) solution for injection, Sodium chloride 9 mg/ml (0.9 %) solution for injection, Sodium chloride 4.5 mg/ml (0.45 %) solution for injection.
The following intravenous fluids may also be used when administered into a running IV catheter: Lactated Ringer's Injection, Lactated Ringer's and glucose 50 mg/ml (5 %) solution for injection.
Remifentanil is compatible with propofol when administered into a running IV catheter.
No other diluents should be used.
The solution is to be inspected visually for particulate matter prior to administration. The solution should only be used if the solution is clear and free from particles.
Ideally, intravenous infusions of remifentanil should be prepared at the time of administration (see Shelf-Life under Storage).
The content of the vial is for single use only. Any unused product or waste material should be disposed of in accordance with local requirements.
Incompatibilities: Remifentanil must not be mixed with other medicinal products except those mentioned in Special Precautions for disposal and other handling.
It should not be admixed with Lactated Ringer's Injection or Lactated Ringer's and glucose 50 mg/ml (5%) solution for injection. Remifentanil should not be mixed with propofol in the same intravenous admixture solution. For compatibility when given into a running i.v. catheter, please see Special Precautions for disposal and other handling.
Administration of Remifentanil into the same intravenous line with blood/serum/plasma is not recommended as non-specific esterase in blood products may lead to the hydrolysis of remifentanil to its inactive metabolite.
Remifentanil should not be mixed with other therapeutic agents prior to administration.